<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between 1986 and 1990, the Pediatric <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group conducted a study in which 198 children younger than 3 years of age with malignant <z:mp ids='MP_0009277'>brain tumors</z:mp> were treated with prolonged postoperative chemotherapy in an effort to delay irradiation and reduce long-term neurotoxicity </plain></SENT>
<SENT sid="1" pm="."><plain>Children younger than 2 years of age received 24 months of chemotherapy followed by irradiation, and those between 2 and 3 years of age received 12 months of chemotherapy plus irradiation </plain></SENT>
<SENT sid="2" pm="."><plain>Chemotherapy was given in 28-day cycles (<z:chebi fb="0" ids="233869">AAB</z:chebi>, <z:chebi fb="0" ids="233869">AAB</z:chebi>), with cycle A = <z:chebi fb="0" ids="28445">vincristine</z:chebi> (0.065 mg/kg) intravenously on days 1 and 8 and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (65 mg/kg) intravenously on day 1, and cycle B = <z:chebi fb="0" ids="27899">cisplatinum</z:chebi> (4 mg/kg) intravenously on day 1 and <z:chebi fb="0" ids="4911">etoposide</z:chebi> (6.5 mg/kg) intravenously on days 3 and 4 </plain></SENT>
<SENT sid="3" pm="."><plain>Five of the 198 children developed <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e>, with a cumulative risk at 8 years of 11.3% (95% confidence interval [CI], 0-39%) </plain></SENT>
<SENT sid="4" pm="."><plain>Four of the five <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> occurred in children younger than 2 years of age at diagnosis, with a cumulative risk at 8 years of 18.9% (CI, 0-70%) </plain></SENT>
<SENT sid="5" pm="."><plain>Initial diagnoses were choroid plexus <z:mp ids='MP_0002038'>carcinoma</z:mp> (2 children), <z:hpo ids='HP_0002888'>ependymoma</z:hpo> (1 child), <z:e sem="disease" ids="C1321878" disease_type="Neoplastic Process" abbrv="DIG">desmoplastic infantile ganglioglioma</z:e> (2 children), and <z:hpo ids='HP_0002885'>medulloblastoma</z:hpo> (1 child) </plain></SENT>
<SENT sid="6" pm="."><plain>Duration from diagnosis of initial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> to <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> was 33, 35, 57, 66, and 92 months </plain></SENT>
<SENT sid="7" pm="."><plain>Three children younger than 2 years of age developed <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e>, that is, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (2 children), both with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 deletions, and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (1 child), after 24 to 26 cycles of chemotherapy, including 8 cycles of <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Two of 3 received craniospinal irradiation (2,560/3,840 cGy) and (3,520/5,320 cGy) </plain></SENT>
<SENT sid="9" pm="."><plain>Time to <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> was 7 years 8 months, 4 years 9 months, and 2 years 9 months </plain></SENT>
<SENT sid="10" pm="."><plain>Two children developed <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, at 5 years 6 months and 2 years 11 months, respectively, after initiation of treatment </plain></SENT>
<SENT sid="11" pm="."><plain>A <z:hpo ids='HP_0100242'>sarcoma</z:hpo> developed after 26 cycles of chemotherapy and no irradiation, and a <z:hpo ids='HP_0002858'>meningioma</z:hpo> developed after 12 cycles of chemotherapy and local craniospinal irradiation </plain></SENT>
<SENT sid="12" pm="."><plain>Potential causative factors for this high rate of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> include prolonged use of <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> and <z:chebi fb="0" ids="4911">etoposide</z:chebi> with or without irradiation </plain></SENT>
</text></document>